Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Heron Therapeutics Inc (HRTX) vs Keysight Technologies Inc (KEYS) Price & Performance

Heron Therapeutics IncTrade
Keysight Technologies IncTrade

Price performance (Past 24H)

Key statistics

Heron Therapeutics Inc vs Keysight Technologies Inc — how do they compare? Heron Therapeutics Inc trades at $0.48 (market cap $91.46M), while Keysight Technologies Inc trades at $322.02 (market cap $53.68B). The key difference: Keysight Technologies Inc is far larger — about 586.9× Heron Therapeutics Inc's market cap, and Keysight Technologies Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.

HRTXKEYS
Market Cap
$91.46M$53.68B
Sector
HealthTechnology
52-Week High
$1.96$373.34
52-Week Low
$0.39$158.51
Enterprise Value
$189.36M$54.03B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Heron Therapeutics Inc

HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.

Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.

Keysight Technologies Inc

Keysight Technologies (KEYS) trades at $313.97, down 0.61% on the day, with technical indicators showing bearish momentum despite recent earnings beats. The company maintains strong profitability with a 17.31% net margin and has secured strategic partnerships, including a European Space Agency contract for 5G network development announced July 15, 2026. Analyst consensus remains strongly bullish with an $396.56 price target, though valuation multiples appear elevated with a P/E of 50.87.

KEYS presents a growth opportunity driven by AI and 5G testing demand, but faces risks from high valuation and volatile cash flows. The stock's near-term direction hinges on Q2 2026 earnings versus the $2.46 EPS estimate, with support at $309 critical for maintaining bullish technical structure.

Returns comparison

Trailing returns across standard periods

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX

About Keysight Technologies Inc

Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.

Read more on KEYS